Comparison of Hormonal Therapy and Chemohormonal Therapy in Patients with Newly Diagnosed Clinical Stage D Prostatic Cancer |
| |
Authors: | Hideaki Miyake Isao Hara Masato Fujisawa Hiroshi Eto Hiroshi Okada Soichi Arakawa Sadao Kamidono |
| |
Institution: | Department of Urology, Kobe University School of Medicine, Kobe, Japan |
| |
Abstract: | Background: In order to examine the usefulness of chemohormonal therapy, we conducted a multicentered randomized trial comparing hormonal therapy, using a luteinizing hormone-releasing hormone (LH-RH) agonist, with chemohormonal therapy, hormonal therapy plus cyclophosphamide (CPM), in patients with newly diagnosed clinical stage D prostatic cancer. Methods: Between January 1991 and March 1995, 41 evaluable patients with stage D prostatic cancer were randomized into 2 groups: group A (hormonal therapy alone), goserelin acetate depot 3.6mg subcutaneously every 4 weeks; group B (chemohormonal therapy), goserelin acetate depot 3.6mg subcutaneously and CPM 1000mg/m2 intravenously every 4 weeks. The responses to the therapies were evaluated based on the criteria of The Japanese Urological Association. Results: There were no significant differences between the 2 groups with regard to objective and subjective response rates. No advantage in chemohormonal therapy was observed in the survival rate and progression-free survival rate. However, the survival rate and progression-free survival rate of responders were significantly higher than those of nonresponders in both groups. When the results were categorized by histologic grade patients with poorly-differentiated adenocarcinoma had significantly higher response rates, survival rates, and disease-progression-free survival rates in Group B compared to similar patients in Group A. Conclusions: We conclude that chemohormonal therapy does not definitely improve the clinical response and prognosis of patients with stage D prostatic cancer; however, for patients with poorly-ditferentiated adenocarcinoma, chemohormonal therapy is a useful treatment. |
| |
Keywords: | stage D prostatic cancer hormonal therapy chemohormonal therapy |
|
|